Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 signaling

Journal of Nutritional Biochemistry

Volumn 20, Issue 9, 2009, Pages 663-676

  Kwon, Gyoo Taik ^a   Cho, Han Jin ^a   Chung, Won Yoon ^b   Park, Kwang Kyun ^b   Moon, Aree ^c   Park, Jung Han Yoon ^a  

^a Hallym University   (South Korea)

^b Yonsei University College of Dentistry   (South Korea)

^c Duksung Women's University   (South Korea)

Author keywords

Activator protein 1; EGF; Jun N terminal kinase; Matrix metalloproteinase; Tissue inhibitor of metalloproteinase

Indexed keywords

ALPHA2 INTEGRIN; EPIDERMAL GROWTH FACTOR; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; ISOLIQUIRITIGENIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN C JUN; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR AP 1; UROKINASE; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL ADHESION; CELL INVASION; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME BINDING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER; PROTEIN DNA BINDING; PROTEIN SECRETION; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

ANDROGENS; CELL ADHESION; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CHALCONES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSCRIPTION FACTOR AP-1; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ALLIUM ASCALONICUM; GLYCYRRHIZA;

EID: 68249127978     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2008.06.005     Document Type: Article

References (63)

1. Surh Y.J. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3 (2003) 768-780
2. Sporn M.B., and Suh N. Chemoprevention of cancer. Carcinogenesis 21 (2000) 525-530
3. Lippman S.M., and Hong W.K. Cancer prevention science and practice. Cancer Res 62 (2002) 5119-5125
4. Clinton S.K., and Giovannucci E. Diet, nutrition, and prostate cancer. Annu Rev Nutr 18 (1998) 413-440
5. Kelloff G.J. Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res 78 (2000) 199-334
6. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
7. Sporn M.B. The war on cancer. Lancet 347 (1996) 1377-1381
8. Kelloff G.J., Lieberman R., Steele V.E., Boone C.W., Lubet R.A., Kopelovitch L., et al. Chemoprevention of prostate cancer: concepts and strategies. Eur Urol 35 (1999) 342-350
9. Kim E.J., Park S.Y., Shin H.K., Kwon D.Y., Surh Y.J., and Park J.H. Activation of caspase-8 contributes to 3,3¢-diindolylmethane-induced apoptosis in colon cancer cells. J Nutr 137 (2007) 31-36
10. Singh R.P., and Agarwal R. Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog 45 (2006) 436-442
11. Yamamoto S., Aizu E., Jiang H., Nakadate T., Kiyoto I., Wang J.C., et al. The potent anti-tumor-promoting agent isoliquiritigenin. Carcinogenesis 12 (1991) 317-323
12. Baba M., Asano R., Takigami I., Takahashi T., Ohmura M., Okada Y., et al. Studies on cancer chemoprevention by traditional folk medicines: XXV. Inhibitory effect of isoliquiritigenin on azoxymethane-induced murine colon aberrant crypt focus formation and carcinogenesis. Biol Pharm Bull 25 (2002) 247-250
13. Yamazaki S., Morita T., Endo H., Hamamoto T., Baba M., Joichi Y., et al. Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma. Cancer Lett 183 (2002) 23-30
14. Jung J.I., Lim S.S., Choi H.J., Cho H.J., Shin H.K., Kim E.J., et al. Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells. J Nutr Biochem 17 (2006) 689-696
15. Kanazawa M., Satomi Y., Mizutani Y., Ukimura O., Kawauchi A., Sakai T., et al. Isoliquiritigenin inhibits the growth of prostate cancer. Eur Urol 43 (2003) 580-586
16. Jung J.I., Chung E., Seon M.R., Shin H.K., Kim E.J., Lim S.S., et al. Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells. Biofactors 28 (2006) 159-168
17. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 98 (2001) 13681-13686
18. Kim E.J., Holthuizen P.E., Park H.S., Ha Y.L., Jung K.C., and Park J.H.Y. Trans-10,cis-12 conjugated linoleic acid inhibits Caco-2 colon cancer cell growth. Am J Physiol Gastrointest Liver Physiol 283 (2002) G357-G367
19. Cho H.J., Kim W.K., Kim E.J., Jung K.C., Park S., Lee H.S., et al. Conjugated linoleic acid inhibits cell proliferation and ErbB3 signaling in HT-29 human colon cell line. Am J Physiol Gastrointest Liver Physiol 284 (2003) G996-G1005
20. Kim E.J., Kang I.J., Cho H.J., Kim W.K., Ha Y.L., and Park J.H. Conjugated linoleic acid downregulates insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells. J Nutr 133 (2003) 2675-2681
21. Lim D.Y., Tyner A.L., Park J.B., Lee J.Y., Choi Y.H., and Park J.H. Inhibition of colon cancer cell proliferation by the dietary compound conjugated linoleic acid is mediated by the CDK inhibitor p21(CIP1/WAF1). J Cell Physiol 205 (2005) 107-113
22. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54 (1994) 5474-5478
23. Cha H.J., Bae S.K., Lee H.Y., Lee O.H., Sato H., Seiki M., et al. Anti-invasive activity of ursolic acid correlates with the reduced expression of matrix metalloproteinase-9 (MMP-9) in HT1080 human fibrosarcoma cells. Cancer Res 56 (1996) 2281-2284
24. Strongin A.Y., Marmer B.L., Grant G.A., and Goldberg G.I. Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2. J Biol Chem 268 (1993) 14033-14039
25. Hackel P.O., Zwick E., Prenzel N., and Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 11 (1999) 184-189
26. Iwashita K., Kobori M., Yamaki K., and Tsushida T. Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells. Biosci Biotechnol Biochem 64 (2000) 1813-1820
27. Maggiolini M., Statti G., Vivacqua A., Gabriele S., Rago V., Loizzo M., et al. Estrogenic and antiproliferative activities of isoliquiritigenin in MCF7 breast cancer cells. J Steroid Biochem Mol Biol 82 (2002) 315-322
28. Ma J., Fu N.Y., Pang D.B., Wu W.Y., and Xu A.L. Apoptosis induced by isoliquiritigenin in human gastric cancer MGC-803 cells. Planta Med 67 (2001) 754-757
29. Wells A. Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res 78 (2000) 31-101
30. Kim H.G., Kassis J., Souto J.C., Turner T., and Wells A. EGF receptor signaling in prostate morphogenesis and tumorigenesis. Histol Histopathol 14 (1999) 1175-1182
31. Di Lorenzo G., Tortora G., D'Armiento F.P., De Rosa G., Staibano S., Autorino R., et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8 (2002) 3438-3444
32. Hegeman R.B., Liu G., Wilding G., and McNeel D.G. Newer therapies in advanced prostate cancer. Clin Prostate Cancer 3 (2004) 150-156
33. Hernes E., Fossa S.D., Berner A., Otnes B., and Nesland J.M. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 90 (2004) 449-454
34. Zellweger T., Ninck C., Bloch M., Mirlacher M., Koivisto P.A., Helin H.J., et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 113 (2005) 619-628
35. Rajan R., Vanderslice R., Kapur S., Lynch J., Thompson R., and Djakiew D. Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone. Prostate 28 (1996) 1-9
36. Freeman M.R., Paul S., Kaefer M., Ishikawa M., Adam R.M., Renshaw A.A., et al. Heparin-binding EGF-like growth factor in the human prostate: synthesis predominantly by interstitial and vascular smooth muscle cells and action as a carcinoma cell mitogen. J Cell Biochem 68 (1998) 328-338
37. Gmyrek G.A., Walburg M., Webb C.P., Yu H.M., You X., Vaughan E.D., et al. Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol 159 (2001) 579-590
38. Fujiuchi Y., Nagakawa O., Murakami K., Fuse H., and Saiki I. Effect of hepatocyte growth factor on invasion of prostate cancer cell lines. Oncol Rep 10 (2003) 1001-1006
39. Hurle R.A., Davies G., Parr C., Mason M.D., Jenkins S.A., Kynaston H.G., et al. Hepatocyte growth factor/scatter factor and prostate cancer: a review. Histol Histopathol 20 (2005) 1339-1349
40. Knudsen B.S., and Edlund M. Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res 91 (2004) 31-67
41. Coussens L.M., and Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 3 (1996) 895-904
42. Liotta L.A., and Stetler-Stevenson W.G. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51 (1991) 5054s-5059s
43. Zhang L., Shi J., Feng J., Klocker H., Lee C., and Zhang J. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis 7 (2004) 327-332
44. Castellino F.J., and Ploplis V.A. Structure and function of the plasminogen/plasmin system. Thromb Haemost 93 (2005) 647-654
45. Kwaan H.C. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 11 (1992) 291-311
46. Brew K., Dinakarpandian D., and Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477 (2000) 267-283
47. Wilhelm S.M., Collier I.E., Marmer B.L., Eisen A.Z., Grant G.A., and Goldberg G.I. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 264 (1989) 17213-17221
48. Stetler-Stevenson W.G., Krutzsch H.C., and Liotta L.A. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 264 (1989) 17374-17378
49. Chirco R., Liu X.W., Jung K.K., and Kim H.R. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25 (2006) 99-113
50. Soula-Rothhut M., Coissard C., Sartelet H., Boudot C., Bellon G., Martiny L., et al. The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells. Exp Cell Res 304 (2005) 187-201
51. Joo Y.E., Seo K.S., Kim H.S., Rew J.S., Park C.S., and Kim S.J. Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer. Dig Dis Sci 45 (2000) 114-121
52. Zeng Z.S., Cohen A.M., Zhang Z.F., Stetler-Stevenson W., and Guillem J.G. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1 (1995) 899-906
53. Wu Z.S., Wu Q., Yang J.H., Wang H.Q., Ding X.D., Yang F., et al. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 122 (2008) 2050-2056
54. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 (2002) 15-18
55. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
56. Chevalier S., Defoy I., Lacoste J., Hamel L., Guy L., Begin L.R., et al. Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis. Mol Cell Endocrinol 189 (2002) 169-179
57. Eccles S.A. Parallels in invasion and angiogenesis provide pivotal points for therapeutic intervention. Int J Dev Biol 48 (2004) 583-598
58. Finkenzeller G., Technau A., and Marme D. Hypoxia-induced transcription of the vascular endothelial growth factor gene is independent of functional AP-1 transcription factor. Biochem Biophys Res Commun 208 (1995) 432-439
59. Cho H.J., Kang J.H., Kwak J.Y., Lee T.S., Lee I.S., Park N.G., et al. Ascofuranone suppresses PMA-mediated matrix metalloproteinase-9 gene activation through the Ras/Raf/MEK/ERK- and Ap1-dependent mechanisms. Carcinogenesis 28 (2007) 1104-1110
60. De Cesare D., Vallone D., Caracciolo A., Sassone-Corsi P., Nerlov C., and Verde P. Heterodimerization of c-Jun with ATF-2 and c-Fos is required for positive and negative regulation of the human urokinase enhancer. Oncogene 11 (1995) 365-376
61. Zutter M.M., Santoro S.A., Painter A.S., Tsung Y.L., and Gafford A. The human alpha 2 integrin gene promoter. Identification of positive and negative regulatory elements important for cell-type and developmentally restricted gene expression. J Biol Chem 269 (1994) 463-469
62. Tsou T.C., Yeh S.C., Tsai F.Y., Chen J.W., and Chiang H.C. Glutathione regulation of redox-sensitive signals in tumor necrosis factor-alpha-induced vascular endothelial dysfunction. Toxicol Appl Pharmacol 221 (2007) 168-178
63. Lee C.K., Son S.H., Park K.K., Park J.H., Lim S.S., and Chung W.Y. Isoliquiritigenin inhibits tumor growth and protects the kidney and liver against chemotherapy-induced toxicity in a mouse xenograft model of colon carcinoma. J Pharmacol Sci 106 (2008) 444-451